Certolizumab for pregnancy in people with APS
Part of Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether certolizumab can improve pregnancy outcomes in people with antiphospholipid syndrome (APS). It targets pregnancy complications related to APS while closely checking safety, infections, and certain health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and under 8 weeks, with a blood test suggesting pregnancy and an ultrasound showing a live embryo of the right size
- You have antiphospholipid syndrome (APS), confirmed by a specific blood test called lupus anticoagulant (LAC)
- Your LAC test is positive at least twice, at least 12 weeks apart (or you were newly diagnosed recently and have one confirmed positive test)
- You are age 18 to 40 years (plus up to 364 days) and can give informed consent
- Your screening blood test shows a hematocrit above 26%
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
This study looks at a specific antibody (anti-C1q) in pregnant women, including those with normal pregnancies, preeclampsia (high blood pressure and protein in urine after 20 weeks), or autoimmune conditions like lupus or antiphospholipid syndrome. The goal is to understand how this antibody might affect pregnancy and help guide care.
This study looks at the typical pregnancy course and outcomes for women with APS or UCTD, two autoimmune-related conditions. It also checks how these conditions and treatments may affect pregnancy, so doctors can better plan care.
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
Hear when a new Pregnancy Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.